Company news

PharmAla Biotech Holdings, Inc. news in 2026

PharmAla Biotech Holdings, Inc.'s news releases, calls and decks from 2026, newest first.

View company

PharmAla Biotech Signs Supply and Data Agreement with Aalborg University Hospital for Danish Randomized Trial of MDMA-Assisted Treatment for Service-Related PTSD

November 9, 2026

PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product

November 5, 2026

Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand

October 8, 2026

PharmAla Biotech Provides Corporate Update, Change of Auditor, Retention of Watertower Research and Oak Hill

September 18, 2026

PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill

September 17, 2026

PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner

August 21, 2026

PharmAla Issues Q3 Financial Statements and AGM Update

July 30, 2026

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

July 21, 2026

PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

July 6, 2026

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

May 20, 2026

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

May 13, 2026

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

April 27, 2026

PharmAla Issues Q2 Financial Statements and Grants Options

April 21, 2026

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

April 20, 2026

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

March 3, 2026

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

February 26, 2026

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

February 23, 2026

PharmAla Announces Changes to Board of Directors

February 10, 2026

PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research

January 8, 2026